RC
CRL icon

RegentAtlantic Capital’s Charles River Laboratories CRL Stock Holding History

RegentAtlantic Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$211K Sell
1,071
-76
-7% -$16.4K 0.01% 627
2022
Q2 		$245K Buy
+1,147
New +$280K 0.01% 591
2015
Q1 		– Sell
-35
Closed -$2.23K – 475
2014
Q4 		$2.23K Buy
+35
New +$2.19K ﹤0.01% 1115

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

RegentAtlantic Capital's CRL Position: Q3 2022 in Review

RegentAtlantic Capital reduced its Charles River Laboratories (CRL) stake by 6.6% in Q3 2022, selling an estimated $16.4K and leaving 1,071 shares worth $211K. The position accounts for 0.01% of the portfolio, ranked #627.

RegentAtlantic Capital first reported a position in CRL in Q4 2014 and has held it in 3 quarters since. The position peaked at $245K in Q2 2022. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • RegentAtlantic Capital held 1,071 shares of Charles River Laboratories worth $211K as of Q3 2022.
  • RegentAtlantic Capital sold 76 Charles River Laboratories shares in Q3 2022, an estimated $16.4K.
  • Charles River Laboratories made up 0.01% of RegentAtlantic Capital's portfolio in Q3 2022, its #627 holding.
  • RegentAtlantic Capital first reported a position in Charles River Laboratories in Q4 2014 and has held it in 3 quarters since.
  • RegentAtlantic Capital's Charles River Laboratories position peaked at $245K in Q2 2022.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.